Verzenio (Abemaciclib) Patent Expiration, LOE Window & CMS Spending
Verzenio (Abemaciclib) by Eli Lilly: FDA Orange Book core substance LOE 2031-09-28, 0 AB generics, $1.45B 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Eli Lilly |
| FDA Application & Pathway | N208716 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-09-28 |
| Last Listed Patent or Exclusivity Date | 2031-09-28 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.45B |
| 2024 Medicare Part D Spend | $1.06B |
| 2024 Medicaid Spend | $393.9M |
| Reported Wholesale Price Change (CA SB 17) | 16 WAC filings (max 19.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.